<DOC>
	<DOCNO>NCT02355821</DOCNO>
	<brief_summary>This study evaluate effect moxonidine versus bisoprolol collagen type 1 C-telopeptide postmenopausal female patient arterial hypertension osteopenia .</brief_summary>
	<brief_title>Comparative Effects Moxonidine Bone Metabolism , Vascular Cellular Aging Hypertensive Postmenopausal Women</brief_title>
	<detailed_description>Several experimental study demonstrate moxonidine may lower activity Na+- independent Cl-/bicarbonate exchanger ( anion exchanger , AE ) play essential role viability osteoclasts crucial bone resorption . The suppression AE proteins activity proven inhibit osteoclast activity reduce bone resorption whereas moxonidine molecule know reduce AE protein activity . Therefore , result experimental study show ability moxonidine inhibit bone resorption effect osteoclast activity . Published data contain information positive effect beta-blockers bone tissue condition . There data clearly demonstrate positive effect beta-blockers bone mass . The propose trial comprehensive study moxonidine effect process cellular vascular age well bone metabolism .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>1 . Female age 45 year old . 2 . Postmenopausal ( absence menstrual period minimum 12 month ) moment Informed Consent sign . 3 . Arterial hypertension grade I / II per ESH/ESC 2013 guideline ( diastolic pressure ≥ 90 &lt; 110 mm Hg , systolic pressure ≥140 &lt; 180 mm Hg ) . 4 . Not achieve BP target &lt; 140/90 mmHg either antihypertensive therapy naive . 5 . Absence moxonidine bisoprolol treatment least 6 month study 6 . Osteopenia lumbar spine and/or proximal part femur ( osteoporosis Tscore 1 2.5 standard deviation [ SD ] ) XRay densitometry . 7 . Signed Informed Consent participation study 1 . Hypersensitivity moxonidine , bisoprolol ingredient respective formulation 2 . Any Contraindications moxonidine , bisoprolol 3 . Osteoporosis ( Тscore 2.5 SD ) . 4 . Primary secondary hyperparathyroidism . 5 . Paget 's disease bone . 6 . History low traumatic bone fracture . 7 . Malabsorption syndrome . 8 . History gastrointestinal surgery . 9 . Severe disturbance peripheral circulation . 10 . Raynaud 's disease . 11 . Symptomatic ( secondary ) hypertension ( cause primary internal disease ) 12 . Morbid obesity ( BMI 40 kg/m2 ) . 13 . Symptoms estrogen deficiency hot flush , night sweat , vaginal dryness 14 . Administration hormonereplacement therapy ( HRT ) intake isoflavones 15 . Secondary hypogonadism . 16 . SistBP ≥180 mm Hg and/or DiastBP ≥110 mm Hg . 17 . Clinical presentation cardiovascular disease : coronary heart disease ( CHD ) , history stroke , transient ischemic attack ( TIA ) , Charcot 's syndrome . 18 . Severe heart failure . 19 . Hemodynamically significant congenital heart disease . 20 . Heart rhythm disorder require permanent use antiarrhythmic medication ( include βadrenoblockers calcium antagonist ) . 21 . Diabetes mellitus genesis . 22 . Severe liver failure . 23 . Severe kidney failure include patient dialysis 24 . Thyroid disease accompany functional disorder ( thyrotoxicosis uncompensated hypothyroidism ) . 25 . Alcohol drug abuse . 26 . Patients oncological disease diagnose within 5 year IC execution . 27 . Inability patient comprehend essence program provide his/her consent participation program . 28 . Patients condition , opinion Investigator make patient unsuitable inclusion base clinical judgment . 29 . Corticosteroid therapy 30 . Participation clinical study whole course investigation include participation study within 30 day prior provide inform consent trial</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cellular age</keyword>
	<keyword>vascular age</keyword>
	<keyword>bone metabolism</keyword>
	<keyword>collagen type 1 C-telopeptide</keyword>
	<keyword>nuclear factor kappa-B ligand ( RANKL )</keyword>
	<keyword>pulse wave velocity</keyword>
	<keyword>telomerase activity</keyword>
</DOC>